Top

Published in:

01-05-2010 | Original Article

Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome

Authors: Zhihui Li, Cuirong Duan, Jinhua He, Tianhui Wu, Mai Xun, Yi Zhang, Yan Yin

Published in: Pediatric Nephrology | Issue 5/2010

Abstract

Treating children with steroid-resistant nephrotic syndrome (SRNS) has been a clinical challenge for pediatricians. We recruited 24 children (18 boys and six girls) with steroid-resistant idiopathic nephrotic syndrome (SRINS) who were <2 years. All patients were administered prednisone 2 mg/kg per day prior to mycophenolate mofetil (MMF). By the end of the eighth week, MMF was initiated at 25–30 mg/kg daily for 6− 12 months. Prednisone dose was reduced stepwise. Biochemical assays were performed every 2 months. Complete remission was achieved in 15 patients, partial remission in six, and no response to MMF was noted in three. With MMF treatment, the levels of urinary protein and serum cholesterol decreased and that of serum albumin increased in a time-dependant manner. We demonstrated the MMF could reduce proteinuria in SRINS children <2 years. Our study suggests that MMF therapy might be an effective strategy for treating SRINS in children <2 years.

El-Husseini A, El-Basuony F, Mahmoud I, Donia A (2004) Co-administration of cyclosporine and ketoconazole in idiopathic childhood nephrosis. Pediatr Nephrol 19:976–981CrossRefPubMed

Ejaz I, Khan HI, Javaid BK, Rasool G (2004) Histopathological diagnosis and outcome of paediatric nephrotic syndrome. J Coll Physicians Surg Pak 14:229–233PubMed

Sorof JM, Hawkins EP, Brewer ED, Boydstun II, Kale AS, Powell DR (1998) Age and ethnicity affect the risk and outcome of focal segmental glomeruloslcerosis. Pediatr Neprhol 12:764–768CrossRef

Okada M, Hino S, Takemura T, Fukushima K (1999) Cyclosporin therapy in children with steroid-resistant nephrotic syndrome. Clin Exp Nephrol 3:S34–S39CrossRef

Allison AC, Eugui EM (1993) Immunosuppressive and other effects of mycophenolic acid ester prodrug, Mycophenolate mofetil. Immunol Rev 136:5–28CrossRefPubMed

Barletta G, Smoyer W, Bunchman T, Flynn J, Kershaw D (2003) Use of Mycophenolate Mofetil in steroid-dependent and –resistant nephrotic syndrome. Pediatr Nephrol 18:833–837CrossRefPubMed

Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933–937CrossRefPubMed

Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114–1120CrossRefPubMed

Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:2059–2065CrossRefPubMed

10.

Moudgil A, Bagga A, Jordan SC (2005) Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 20:1376–1381CrossRefPubMed

11.

Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013–2020CrossRefPubMed

12.

Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71–76CrossRefPubMed

13.

Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H (2005) Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 20:1265–1268CrossRefPubMed

14.

Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 20:914–919CrossRefPubMed

15.

Ulinski T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482–485CrossRefPubMed

16.

Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19:101–104CrossRefPubMed

17.

Chandra M, Susin M, Abitbol C (2000) Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 14:224–226CrossRefPubMed

18.

Peña A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, Alonso A, Picazo ML, Navarro M (2007) Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy. Pediatr Nephrol 22:1875–1888CrossRefPubMed

19.

Montané B, Abitbol C, Chandar J, Strauss J, Zilleruelo G (2003) Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 18:772–777CrossRefPubMed

20.

International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564CrossRef

21.

Srivastava T, Simon SD, Alon US (1999) High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13:13–18CrossRefPubMed

22.

McBryde KD, Kershaw DB, Smoyer WE (2001) Pediatric steroid-resistant nephrotic syndrome. Curr Probl Pediatr Adolesc Health Care 31:280–307PubMed

23.

Feng SP, Huang JP, Xu M, Li S, Luo W, Lai XJ (2007) Clinical presentations and pathologic features of 25 cases of infant nephrotic syndrome. Zhongguo Dang Dai Er Ke Za Zhi 9:151–152PubMed

24.

Yu L, Wen ZY, Hua SD, Zhang YX, Huang YH, Meiying Z, Xiaoshu Y (2002) Analysis of clinical characteristics in infantile nephrotic syndrome. Chinese Journal of Practical Pediatrics 17:553–555

25.

Wenyan H, Mingchang H, Xingyou J, Yi C (1995) Nephrotic syndrome in infants below 3-year-old. Acta Universitatis Medicinalis Nanjing 15:326–327

26.

Fangyun S, Xingyu H, Yingqing G, Moyi G, Xiurong Z (1994) Long term follow-up of nephrotic syndrome in children under 2 years. Chin J Pediatr 32:276–278

27.

Wang JG, Zhou ZL, Pan T, Li CC, Yang Q (2002) Integrated traditional Chinese and Western medicine for infantile nephrotic syndrome-150 cases report. Shanghai Journal of Traditional Chinese Medicine 2:27–29

28.

Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88PubMed

29.

Griswold WR, Tune BM, Reznik VM, Vazquez M, Prime DJ, Brock P, Mendoza SA (1987) Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents. Nephron 46:73–77CrossRefPubMed

30.

Goonasekera CD, Koziell AB, Hulton SA, Dillon MJ (1998) Vincristine and focal segmental sclerosis: do we need a multicentre trial? Pediatr Nephrol 12:284–289CrossRefPubMed

31.

Almeida MP, Almeida HA, Rosa FC (1994) Vincristine in steroid-resistant nephrotic syndrome. Pediatr Nephrol 8:79–80CrossRefPubMed

32.

Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE (1996) Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 7:543–549PubMed

33.

Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group (2001) Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59:1484–1490CrossRef

34.

Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56:2220–2226CrossRefPubMed

35.

Zaffanello M, Brugnara M, Franchini M (2007) Therapy for children with henoch-schonlein purpura nephritis: a systematic review. ScientificWorldJournal 7:20–30CrossRefPubMed

36.

Algoet C, Proesmans W (2003) Renal biopsy 2–9 years after Henoch Schönlein purpura. Pediatr Nephrol 18:471–473PubMed

37.

Liu HM, Xu H, Zhou LJ, Zhang J (2007) Efficacy of mycophenolate mofetil and methylprednisolone alternate-day therapy in childhood lupus nephritis. Chinese Journal of Practical Pediatrics 22:137–138

38.

Appel AS, Appel GB (2009) An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 5:132–142CrossRefPubMed

39.

Xu G, Tu W, Jiang D, Xu C (2009) Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 29:362–367CrossRefPubMed

Title: Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome
Authors: Zhihui Li
Cuirong Duan
Jinhua He
Tianhui Wu
Mai Xun
Yi Zhang
Yan Yin
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 5/2010
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-009-1375-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin

Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury

On the relationship between glomerular filtration rate and serum creatinine in children

Fluid and electrolyte therapy: a primer

Idiopathic membranous nephropathy associated with polycystic kidney disease

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure